Free Trial

Ardelyx (ARDX) Competitors

Ardelyx logo
$4.93 -0.21 (-4.09%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$5.03 +0.10 (+2.05%)
As of 03/28/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARDX vs. ADMA, PTCT, RNA, ACLX, OGN, ZLAB, RARE, SWTX, AKRO, and ALVO

Should you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Avidity Biosciences (RNA), Arcellx (ACLX), Organon & Co. (OGN), Zai Lab (ZLAB), Ultragenyx Pharmaceutical (RARE), SpringWorks Therapeutics (SWTX), Akero Therapeutics (AKRO), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry.

Ardelyx vs.

ADMA Biologics (NASDAQ:ADMA) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, community ranking, earnings, profitability and analyst recommendations.

ADMA Biologics has a net margin of 17.80% compared to Ardelyx's net margin of -11.73%. ADMA Biologics' return on equity of 53.20% beat Ardelyx's return on equity.

Company Net Margins Return on Equity Return on Assets
ADMA Biologics17.80% 53.20% 26.07%
Ardelyx -11.73%-24.87%-10.51%

ADMA Biologics presently has a consensus target price of $22.50, suggesting a potential upside of 11.06%. Ardelyx has a consensus target price of $10.95, suggesting a potential upside of 122.11%. Given Ardelyx's higher probable upside, analysts plainly believe Ardelyx is more favorable than ADMA Biologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADMA Biologics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25
Ardelyx
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.00

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by insiders. Comparatively, 5.9% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ADMA Biologics has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADMA Biologics$426.45M11.23-$28.24M$0.8224.71
Ardelyx$333.62M3.52-$39.14M-$0.16-30.81

In the previous week, ADMA Biologics had 12 more articles in the media than Ardelyx. MarketBeat recorded 16 mentions for ADMA Biologics and 4 mentions for Ardelyx. ADMA Biologics' average media sentiment score of 1.34 beat Ardelyx's score of 0.70 indicating that ADMA Biologics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ADMA Biologics
11 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ardelyx
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ardelyx received 123 more outperform votes than ADMA Biologics when rated by MarketBeat users. However, 72.13% of users gave ADMA Biologics an outperform vote while only 67.46% of users gave Ardelyx an outperform vote.

CompanyUnderperformOutperform
ADMA BiologicsOutperform Votes
414
72.13%
Underperform Votes
160
27.87%
ArdelyxOutperform Votes
537
67.46%
Underperform Votes
259
32.54%

ADMA Biologics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Summary

ADMA Biologics beats Ardelyx on 13 of the 19 factors compared between the two stocks.

Remove Ads
Get Ardelyx News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARDX vs. The Competition

MetricArdelyxPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.18B$6.91B$5.63B$7.83B
Dividend YieldN/A2.73%4.57%4.00%
P/E Ratio-30.817.1723.3318.67
Price / Sales3.52220.47388.4691.01
Price / CashN/A65.6738.1634.64
Price / Book6.756.396.894.23
Net Income-$39.14M$142.12M$3.20B$247.15M
7 Day Performance-3.90%-5.18%-3.02%-2.17%
1 Month Performance-8.02%-7.49%1.63%-5.68%
1 Year Performance-32.47%-8.78%9.74%-0.67%

Ardelyx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARDX
Ardelyx
4.3563 of 5 stars
$4.93
-4.1%
$10.95
+122.1%
-32.5%$1.18B$333.62M-30.8190
ADMA
ADMA Biologics
2.4353 of 5 stars
$20.32
+2.6%
$22.50
+10.7%
+207.0%$4.80B$426.45M72.57530Positive News
PTCT
PTC Therapeutics
3.4572 of 5 stars
$57.03
-0.2%
$64.00
+12.2%
+86.5%$4.50B$806.78M-9.601,410Positive News
RNA
Avidity Biosciences
2.5556 of 5 stars
$33.30
+8.0%
$66.69
+100.3%
+23.8%$4.00B$10.90M-11.56190
ACLX
Arcellx
2.3003 of 5 stars
$72.48
+4.5%
$108.46
+49.6%
-2.3%$3.98B$107.94M-102.0880Positive News
OGN
Organon & Co.
4.7565 of 5 stars
$15.35
-0.3%
$20.80
+35.5%
-22.8%$3.96B$6.40B4.6110,000News Coverage
Positive News
ZLAB
Zai Lab
2.384 of 5 stars
$35.67
+1.7%
$47.37
+32.8%
+132.8%$3.91B$398.99M-12.881,950Analyst Forecast
Positive News
Gap Up
RARE
Ultragenyx Pharmaceutical
4.4238 of 5 stars
$39.36
+0.5%
$91.71
+133.0%
-19.0%$3.64B$560.23M-6.211,276Analyst Forecast
News Coverage
Positive News
SWTX
SpringWorks Therapeutics
2.3558 of 5 stars
$48.51
-2.8%
$73.20
+50.9%
-3.7%$3.64B$191.59M-13.94230Positive News
AKRO
Akero Therapeutics
4.2415 of 5 stars
$45.08
-0.3%
$76.29
+69.2%
+69.1%$3.59BN/A-12.0230Insider Trade
Positive News
Gap Up
ALVO
Alvotech
2.012 of 5 stars
$11.56
-0.1%
$18.00
+55.7%
-21.8%$3.49B$391.87M-6.251,026Earnings Report
News Coverage
Remove Ads

Related Companies and Tools


This page (NASDAQ:ARDX) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners